GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLight Life Sciences Ltd (NAS:BOLT) » Definitions » Cash per Share

BioLight Life Sciences (BioLight Life Sciences) Cash per Share : $0.04 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is BioLight Life Sciences Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). BioLight Life Sciences's Cash per Share for the quarter that ended in Dec. 2023 was $0.04.


BioLight Life Sciences Cash per Share Historical Data

The historical data trend for BioLight Life Sciences's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLight Life Sciences Cash per Share Chart

BioLight Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.28 0.19 0.10 0.05

BioLight Life Sciences Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.12 0.08 0.10 0.04

BioLight Life Sciences Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

BioLight Life Sciences's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

BioLight Life Sciences's Cash per Share for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLight Life Sciences  (NAS:BOLT) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


BioLight Life Sciences Cash per Share Related Terms

Thank you for viewing the detailed overview of BioLight Life Sciences's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLight Life Sciences (BioLight Life Sciences) Business Description

Traded in Other Exchanges
Address
Kiryat Atidim, Building 7, Entrance 1, 2nd Floor, Tel-Aviv, ISR, 6158101
BioLight Life Sciences Ltd is an emerging global ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.

BioLight Life Sciences (BioLight Life Sciences) Headlines

From GuruFocus

Bolt Biotherapeutics to Present at February Investor Conferences

By Stock market mentor Stock market mentor 02-01-2023

Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

By Value_Insider Value_Insider 12-14-2022